Show simple item record

dc.contributor.authorNombela, Paz
dc.contributor.authorLozano, Rebeca
dc.contributor.authorAytes, Alvaro
dc.contributor.authorMateo, Joaquin
dc.contributor.authorOlmos, David 
dc.contributor.authorCastro, Elena 
dc.date.accessioned2019-07-02T08:33:22Z
dc.date.available2019-07-02T08:33:22Z
dc.date.issued2019-03-12
dc.identifier.citationCancers (Basel). 2019;11(3). pii: E352es_ES
dc.identifier.issn2072-6694es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7836
dc.description.abstractGermline and somatic aberrations in DNA damage repair (DDR) genes are more prevalent in prostate cancer than previously recognized, with BRCA2 as the most commonly altered gene. Germline mutations in BRCA2 have been linked to poor prognosis when patients are managed under the protocols currently approved for prostate cancer. The impact of germline mutations in other DDR genes beyond BRCA2 remain unclear. Importantly, a quarter of prostate cancer patients identified as germline mutation carriers lack a family history of cancer. The clinical implications of somatic DDR defects are yet to be elucidated. Poly ADP-ribose polymerase (PARP) inhibitors and platinum-based chemotherapy have proven to be effective in the treatment of other tumor types linked to BRCA1 and BRCA2 alterations and several trials are currently evaluating their efficacy in prostate cancer. Here, we summarize the available evidence regarding the prevalence of somatic and germline DDR defects in prostate cancer; their association with clinical outcomes; the trials assessing the efficacy of new therapies that exploit DDR defects in prostate cancer and briefly discuss some uncertainties about the most appropriate management for these patients.es_ES
dc.description.sponsorshipFunding: R.L., A.A., and D.O. were funded by the Instituto de Salud Carlos III (grants CM17/00221 to R.L., PI16/01070 and CP15/00090 to A.A., and PI16/01565 to D.O.). A.A. is supported by grants from the European Association of Urology Research Foundation (EAURF/407003/XH), a Department of Defense Award (W81XWH-18-1-0193), Fundacion BBVA, CERCA Program/Generalitat de Catalunya, and FEDER funds/European Regional Development Fund (ERDF)-A Way to Build Europe. D.O. was funded by grants fromthe Ministerio de Economía y Empresa (RYC-2015-18625). E.C. and J.M. were supported by Young Investigator Awards from the Prostate Cancer Foundation. J.M. and D.O. were supported by an Impact Award from the Department of Defense US (PC170510P2).es_ES
dc.language.isoenges_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectBRCA2es_ES
dc.subjectDDRes_ES
dc.subjectDNA damage and repaires_ES
dc.subjectPARP inhibitorses_ES
dc.subjectprostate canceres_ES
dc.titleBRCA2 and Other DDR Genes in Prostate Canceres_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID30871108es_ES
dc.format.volume11es_ES
dc.format.number3es_ES
dc.format.page352es_ES
dc.identifier.doi10.3390/cancers11030352es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderEuropean Association of Urology
dc.contributor.funderFundación BBVA
dc.contributor.funderUnited States Department of Defense
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/cancers11030352.es_ES
dc.identifier.journalCancerses_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Cáncer de Próstataes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01565es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01070es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ESCM17/00221es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional